| 宗欣,陈罡毅.大数据背景下对我国药品研发战略管理的思考[J].中国药事,2019,33(4):365-369 |
| 大数据背景下对我国药品研发战略管理的思考 |
| Thoughts on Strategic Management of Drug Research and Development in China under the Background of Big Data |
| 投稿时间：2018-10-12 |
| DOI：10.16153/j.1002-7777.2019.04.002 |
| 中文关键词: 大数据 药品研发 战略管理 |
| 英文关键词: big data drug research and development(R&D) strategic management |
| 基金项目: |
|
| 摘要点击次数: 1067 |
| 全文下载次数: 788 |
| 中文摘要: |
| 随着“互联网+战略”的持续深入推进以及信息技术的高速发展，大数据技术和观念已经逐步渗透到社会的各行各业。具体到药品研发领域，在药品研发过程中应用大数据技术进行管理，将会在极大程度上提高海量药品相关数据的筛选和管理效率，并为研发决策提供科学指引。本文以大数据和特点的分析为导入，着重分析了药品研发战略管理的核心以及大数据在其中的重要作用，并对大数据应用于我国药物研发战略管理提出了对策和建议。 |
| 英文摘要: |
| With the continuous advancement of Internet plus strategy and the rapid development of information technology, technology and concept of big data has gradually penetrated into all aspects. As far as the field of drug research and development (R&D) is concerned, the application of the technology of big data in the management of the drug R&D will greatly improve the efficiency of screening and management of large quantities of drug-related data and provide scientific guidance for R&D decisions. Based on the analysis of characteristics of big data, this paper focuses on the analysis of the core of the strategic management of drug R&D and the important role of big data in the process of R&D, and puts forward countermeasures and suggestions for the application of big data in strategic management of drug R&D in China. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |